Financials data is unavailable for this security.
View more
Year on year Shanghai Shenqi Pharmaceutical Investment Management Co Ltd had relatively flat revenues (2.39bn to 2.34bn), though the company grew net income 17.41% from 48.55m to 57.00m. A reduction in the selling, general and administrative costs as a percentage of sales from 46.56% to 41.60% was a component in the net income growth despite flat revenues.
| Gross margin | 45.89% |
|---|---|
| Net profit margin | 2.79% |
| Operating margin | 3.45% |
| Return on assets | 1.95% |
|---|---|
| Return on equity | 2.59% |
| Return on investment | 2.48% |
More ▼
Cash flow in CNYView more
In 2023, Shanghai Shenqi Pharmaceutical Investment Management Co Ltd increased its cash reserves by 9.12%, or 59.72m. The company earned 215.59m from its operations for a Cash Flow Margin of 9.21%. In addition the company used 39.75m on investing activities and also paid 116.12m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 4.34 |
|---|---|
| Tangible book value per share | 3.70 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.87 |
|---|---|
| Quick ratio | 2.50 |
| Total debt/total equity | 0.1797 |
|---|---|
| Total debt/total capital | 0.1488 |
More ▼
Growth rates in CNY
Year on year, growth in dividends per share remained flat while earnings per share excluding extraordinary items increased 17.41%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.82% |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 88.86% |
| EPS growth(5 years) | -11.80 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 32.85 |
More ▼
